🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications
Irish Medicines Database · HPRA register

MIRAPEXIN 3.15 mg prolonged-release tablets

Authorisation EU/1/97/051/25-27 · Boehringer Ingelheim International GmbH

← All medicines
MIRAPEXIN 3.15 mg prolonged-release tablets
Licence EU/1/97/051/25-27 · Unknown
Licence holder
Boehringer Ingelheim International GmbH (all products →)
Active substance
Pramipexole dihydrochloride monohydrate
Dosage form
Prolonged-release tablet
Route of administration
Oral use
ATC codes
N04BC, N04BC05
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
New active substance (Article 8(3) of Directive No 2001/83/EC)

Data: Health Products Regulatory Authority (HPRA) open dataset, licensed CC BY 4.0, published 04 Jul 2026. This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.